Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pan Tumor Clear all
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

NCT01473095
View directory record Official record
Conditions
Solid Tumor, Malignant Lymphoma, Tumor
Interventions
ARQ 092
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT04645160
View directory record Official record
Conditions
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Interventions
Tivozanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

NCT02575508
View directory record Official record
Conditions
Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Oxaliplatin, pan FGFR Kinase Inhibitor BGJ398, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jul 23, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

NCT01149668
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 23, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

NCT03834220
View directory record Official record
Conditions
Solid Tumor
Interventions
Debio 1347
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

NCT04879121
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

NCT01441128
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell, Carcinoma, Large Cell
Interventions
PF-02341066/PF-00299804
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 5:01 PM EDT
Not listed No phase listed Observational

A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

NCT05308784
View directory record Official record
Conditions
Pan-cancer
Interventions
Cellworks Singula and Ventura reports
Other
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
Not listed
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 23, 2026, 5:01 PM EDT
Completed No phase listed Observational

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

NCT02492815
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
1,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NCT07458347
View directory record Official record
Conditions
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
Interventions
KST-6051
Drug
Lead sponsor
Kestrel Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 1 Interventional

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

NCT06096974
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
YL-17231
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 23, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study

NCT01202136
View directory record Official record
Conditions
Pancreatic Cysts, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920
View directory record Official record
Conditions
Solid Tumor
Interventions
Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jul 23, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT03668119
View directory record Official record
Conditions
Pan Tumor
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Santa Monica, California • Denver, Colorado • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 23, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

NCT06208124
View directory record Official record
Conditions
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions
IMM-6-415
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 23, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

NCT05084859
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 23, 2026, 5:01 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional Results available

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Erdafitinib, Midazolam, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
25
States / cities
Sedona, Arizona • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00933985
View directory record Official record
Conditions
Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate, liposomal vincristine sulfate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Jul 23, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors
Interventions
Raludotatug deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Marietta, Georgia • Ann Arbor, Michigan • East Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Interventions
BLU-924
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 5:01 PM EDT
Not listed No phase listed Observational

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports

NCT05693831
View directory record Official record
Conditions
Cancer, Relapsed Cancer, Refractory Cancer
Interventions
Cellworks Report
Other
Lead sponsor
Cellworks Group Inc.
Industry
Eligibility
Not listed
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Jul 23, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jul 23, 2026, 5:01 PM EDT
Active, not recruiting Early Phase 1 Interventional

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

NCT04544098
View directory record Official record
Conditions
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Interventions
177Lu-DOTATATE
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 5:01 PM EDT